Growing Acceptance of GLP-1 Medications for Weight Management in El Paso

GLP-1 medications, including Ozempic and Wegovy, are increasingly recognized for their potential benefits beyond obesity and diabetes management. Research indicates that these drugs can aid in weight loss and improve metabolic health for individuals with lower BMI, challenging traditional prescribing guidelines that limit use to those with a BMI of 30 or higher. New definitions of obesity could allow more individuals to access these medications, potentially impacting one in five adults previously classified as overweight. This shift highlights the importance of addressing weight-related health risks early, as even modest weight loss can lead to significant health improvements, such as lower blood pressure and reduced diabetes risk.

Key Details: • GLP-1 medications can be prescribed off-label for patients with BMIs below 27, though insurance coverage is rare. • New obesity definitions may classify individuals with a BMI of 25 or higher as obese if they have related health issues. • Small weight losses (5-10%) can lead to significant health benefits, including lower blood pressure and reduced cancer risk.